Clinical Trials Report for November 2015 | Aplastic Anemia and MDS International Foundation

Clinical Trials Report for November 2015

We have highlighted some clinical trials currently recruiting patients. Each has a specific purpose related to aplastic anemia, MDS, or PNH. These clinical trials (also known as research studies) were obtained from www.clinicaltrials.gov, the federal web site that presents information on clinical trials worldwide. To narrow down your search criteria, use the advanced search feature found on the home page.

  • If you want to see only studies that are currently recruiting patients, select that option from the recruitment field at the beginning of the advanced search.
  • To locate a clinical trial in your state or region, simply select this from the locations field in the middle of the page.
  • To search in predetermined time period, indicate the starting and ending dates in the date received field at the bottom of the page.
  • There are many more criteria available to search in www.clincial trials.gov through its advanced search features.

Should you consider a clinical trial? Ask your doctor or contact the trial’s study coordinators for further information. Learn more in the Clinical Trials section.

Search for aplastic anemia studies actively recruiting patients. The following are a sample of the 78 open studies recruiting aplastic anemia patients in the United States.

Title/Link to more information

Study Purpose

Study Coordinator

Extended Dosing with Eltrombopag for Severe Aplastic Anemia The main goal of this study is to determine if whether 6 months of treatment with eltrombopag for Severe Aplastic Anemia This study is being conducted at the National Institutes of Health Clinical Center

Contact: Marlene Peters-Lawrence, R.N
(301)-443-6144  mpeters@nhlbi.nih.gov

Contact: Thomas Winker, MD
(301)-451-7142  winklert@nhlbi.nih.gov

Please refer to this study by its ClinicalTrials.gov identifier: NCT01891994
A Description of Bacteria in the Mouths of Patients With Severe Aplastic Anemia The purpose of this study is to describe the types of bacteria found in the mouths of patients who have severe aplastic anemia (SAA) and are treated with drugs that suppress the immune system or with stem cell transplant. People with SAA who receive these treatments are more likely to get infections. Studies show that there might be a link between the bacteria in your mouth and those bacteria that can cause infections. The bacteria found in the mouths of patients with SAA will be described. This study is being conducted at the National Institutes of Health Clinical Center

Contact: Nancy Ames, RN 301-451-0565 names@mail.cc.nih.gov

Please refer to this study by its ClinicalTrials.gov identifier: NCT01900119

Seach for myelodysplastic syndromes studies actively recruiting patients. The following MDS studies are a sample of the 313 studies recruiting MDS patients in the United States.

Title/Link to more information

Study Purpose

Study Coordinator

Efficacy and Safety Study of CC-486 (ORAL AZACITIDINE) in Subjects With Myelodysplastic Syndromes
The primary purpose of this study is to Evaluate the efficacy and safety of CC-486 (ORAL AZACITIDINE) in subjects with myelodysplastic syndromes. This study is being conducted by Celgene in KY, NJ, NY, TX, and France.

Contact: Associate Director, Clinical Trial Disclosure. 1-888-260-1599

Please refer to this study by its ClinicalTrials.gov identifier: NCT02281084
Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

This pilot clinical trial studies the feasibility of having induction chemotherapy in an outpatient setting. Patients with acute leukemia (AML) or advanced myelodysplastic syndrome (MDS), at least 18 years of age will be examined. Treating eligible patients with induction chemotherapy in an outpatient setting may save in healthcare cost and improve a patients' quality of life. This study is being conducted by Fred Hutchinson Cancer Research Cancer/University of Washington Cancer Consortium multiple cities MT and WA.
Bozeman Deaconess Cancer Center
Boseman, MT

Contact: Jack O. Hensold , 406-585-5070 
   
Kadlec Clinic Hematology and Oncology Kennewick, WA
Contact: Thomas A. Rado    509-783-0144     
 
Evergreen Health Medical Center    
Kirkland, WA
Contact: Aimee D. Kohn    425-899-3953     

Skagit Valley Hospital
Mount Vernon, WA
Contact: Kiarash Kojouri    360-428-2146     

Olympic Medical Center
Port Angeles, WA
Contact: Thomas D. Kummet    360-683-9895    
 
Group Health Cooperative
Redmond, WA
Contact: Eric Y. Chen    425-502-3690
    
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, WA
Contact: Pamela S. Becker   206-616-1589
     
Multicare Health System
Tacoma, WA
Contact: John A. Keech    253-403-1677  
  
Wenatchee Valley Hospital and Clinics
Wenatchee, WA
Contact: Mitchell A. Garrison    509-663-8711    
 
Please refer to this study by its ClinicalTrials.gov identifier: NCT01807091
A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome


This is a study to evaluate PF-04449913 (an inhibitor of the Hedgehog pathway) in Acute Myeloid Leukemia and high-risk Myelodysplastic Syndrome in combination with standard agents used to treat these diseases This study is being conducted in AL,
CA, FL, GA, IL, KS, MD, MO, NJ, NY, OH,
TN, TX, WA, and Canada.

Contact: Pfizer CT. gov Call Center
Esperanza Papadopoulos, M.D
1-800-718-1021   

Please refer to this study by its ClinicalTrials.gov identifier: NCT01546038

 

Please search for a list of current paroxysmal nocturnal hemoglobinuria studies actively recruiting patients. The following are a recent sample of the 7 studies recruiting PNH patients in the United States.

Title/Link to more information

Study Purpose

Study Coordinator

A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH This study will be the initial exploration of APL-2 in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of APL-2 will guide decisions to further develop the drug. This study is being conducted at the University of Louisville, KY

Contact: Candace Depp        pnh@apellis.com

Please refer to this study by its ClinicalTrials.gov identifier: NCT02264639